A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Nave Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
A study for patients with acute myeloid leukemia using study drug Venetoclax in combination with Azacitidine
Sponsor: AbbVie, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR1251
Contact: Daniel Lee, MD: 212-851-4872 / djl2164@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy (how well the study drug works) and safety of venetoclax in combination with azacitidine in subjects who have not been treated for their acute myeloid leukemia (AML). The tolerability (the degree to which evident adverse effects can be tolerated by the patient) of venetoclax will also be evaluated.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Do you have confirmed diagnosis of acute myeloid leukemia (AML)? Yes No
Are you older than 18 years of age? Yes No
Have you received experimental therapies for acute myeloid leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Daniel Lee, MD
djl2164@cumc.columbia.edu
212-851-4872
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE